Phase 2
N=301
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
Asthma
Bottom Line
View on ClinicalTrials.gov: NCT01591044 ↗Enrolled (actual)
301
Serious AEs
0.0%
Results posted
Sep 2016
Primary outcome: Primary: Change in FEV1 — -0.40; 0.69; -0.59 percentage of change
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Placebo (Drug); R940343 1mg (Drug); R940343 2mg (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Rigel Pharmaceuticals
- Primary completion
- Jul 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in FEV1 |
-0.40; 0.69; -0.59 | — |
Summary
The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.
Eligibility Criteria
Inclusion Criteria
- Clinical history of asthma
- Ability to perform spirometry
Exclusion Criteria
- Chronic obstructive pulmonary disease or bronchiectasis
- Upper or lower respiratory infection
Data sourced from ClinicalTrials.gov (NCT01591044). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.